<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00165191</url>
  </required_header>
  <id_info>
    <org_study_id>98-048</org_study_id>
    <nct_id>NCT00165191</nct_id>
  </id_info>
  <brief_title>Doxorubicin, Cisplatin, 5-Fluorouracil in Patients With Advanced Adenocarcinoma of the Stomach or Esophagus</brief_title>
  <official_title>A Phase II Study of Doxorubicin, Cisplatin, and 5-Fluorouracil in Patients With Advanced Adenocarcinoma of the Stomach or Esophagus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dana-Farber Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Dana-Farber Cancer Institute</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to collect information on the anti-tumor activity of the&#xD;
      combination doxorubicin, cisplatin, and 5-fluorouracil when given to patients with advanced&#xD;
      esophageal or gastric adenocarcinoma. We will also be collecting information about the side&#xD;
      effects and safety of this combination.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Patients will receive cisplatin and doxorubicin intravenously once every 3 weeks. In&#xD;
           addition to cisplatin and doxorubicin, patients will receive 5-fluorouracil&#xD;
           intravenously as a continuous infusion for the duration of the study. In order to do&#xD;
           this, patients will receive an infusion pump that can be carried with them. Treatment&#xD;
           cycles will be repeated every 21 days for a maximum of 8 cycles.&#xD;
&#xD;
        -  Prior to enrollment in this study and while the patient is receiving the therapy,&#xD;
           routine blood tests and x-ryas (including chest x-rays and CT scans) will be performed&#xD;
           to check the body's response to the treatment. Blood tests will be checked once a week&#xD;
           and chest x-rays and CT scans will be checked every 6 weeks.&#xD;
&#xD;
        -  Patients with progressive disease or intolerable side effects will be removed from the&#xD;
           study. Patients with stable disease or tumor response will continue therapy for a&#xD;
           maximum of 8 cycles.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 1998</start_date>
  <completion_date type="Actual">January 2006</completion_date>
  <primary_completion_date type="Actual">January 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the activity of doxorubicin, cisplatin and continuous infusion of 5-fluorouracil in patients with measurable, locally unresectable or metastatic adenocarcinoma of the stomach, GE junction, or esophagus.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess the safety of doxorubicin, cisplatin and 5-fluorouracil when given in combination to treat this patient population</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>evaluate the survival of this patient population.</measure>
  </secondary_outcome>
  <enrollment>32</enrollment>
  <condition>Adenocarcinoma of Stomach</condition>
  <condition>Adenocarcinoma of GE Junction</condition>
  <condition>Adenocarcinoma of Esophagus</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-fluorouracil</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Measurable, locally unresectable or metastatic adenocarcinoma of the stomach, GE&#xD;
             junction or esophagus&#xD;
&#xD;
          -  No more than one prior chemotherapy regimen&#xD;
&#xD;
          -  ECOG performance status of &lt; or equal to 2&#xD;
&#xD;
          -  Life expectancy &gt; 12 weeks&#xD;
&#xD;
          -  ANC &gt; 1,500/mm3&#xD;
&#xD;
          -  Hemoglobin &gt; 9.0 gm/dl&#xD;
&#xD;
          -  Platelets &gt; 100,000/mm3&#xD;
&#xD;
          -  SGOT &lt; 3 x ULN&#xD;
&#xD;
          -  Total bilirubin &lt; 2.0 mg/dl&#xD;
&#xD;
          -  Creatinine &lt; 1.5 mg/dl&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior cisplatin or doxorubicin as neoadjuvant or adjuvant therapy with in 1 year of&#xD;
             study entry&#xD;
&#xD;
          -  Clinically apparent central nervous system metastases or carcinomatous meningitis&#xD;
&#xD;
          -  Myocardial infarction in the past 6 months&#xD;
&#xD;
          -  Major surgery in the past 2 weeks&#xD;
&#xD;
          -  Uncontrolled serious medical or psychiatric illness&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
          -  Concurrent malignancy of any site, except limited basal cell carcinoma or squamous&#xD;
             cell carcinoma of the skin or carcinoma in situ of the cervix&#xD;
&#xD;
          -  History or clinical evidence of congestive heart failure&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthew Kulke, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dana-Farber Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2009</verification_date>
  <study_first_submitted>September 9, 2005</study_first_submitted>
  <study_first_submitted_qc>September 9, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 14, 2005</study_first_posted>
  <last_update_submitted>April 27, 2009</last_update_submitted>
  <last_update_submitted_qc>April 27, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 28, 2009</last_update_posted>
  <keyword>doxorubicin</keyword>
  <keyword>cisplatin</keyword>
  <keyword>5-fluorouracil</keyword>
  <keyword>stomach cancer</keyword>
  <keyword>esophagus cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

